Nancy Yu
Genentech
12 Papers
18 Citations
Nancy Yu is an academic researcher from Genentech. The author has contributed to research in topics: PEGylation & Epithelial–mesenchymal transition. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer
Susanna Stinson,Mark R. Lackner,Alex T. Adai,Nancy Yu,Hyojin Kim,Carol O'Brien,Jill M. Spoerke,Suchit Jhunjhunwala,Zachary Boyd,Thomas Januario,Robert J. Newman,Peng Yue,Richard Bourgon,Zora Modrusan,Howard M. Stern,Søren Warming,Frederic J. de Sauvage,Lukas C. Amler,Ru-Fang Yeh,David Dornan +19 more
TL;DR: The data suggest that combining inhibition of the EGFR-RAS-ERK pathway with standard chemotherapy could, by limiting miR-221/222 production, provide a strategy to combat metastasis in the basal-like subtype of breast cancer.
328
Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
David Dornan,Fiona Bennett,Yvonne Chen,Mark S. Dennis,Dan L. Eaton,Kristi Elkins,Dorothy French,Mary Ann T. Go,Andrew Jack,Jagath Reddy Junutula,Hartmut Koeppen,Jeffrey Lau,Jacqueline McBride,Andy C. Rawstron,Xiaoyan Shi,Nancy Yu,Shang-Fan Yu,Peng Yue,Bing Zheng,Allen J. Ebens,Andrew Polson +20 more
TL;DR: The generation of an antibody-drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker is described.
313
miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer
Susanna Stinson,Mark R. Lackner,Alex T. Adai,Nancy Yu,Hyojin Kim,Carol O'Brien,Jill M. Spoerke,Suchit Jhunjhunwala,Zachary Boyd,Thomas Januario,Robert J. Newman,Peng Yue,Richard Bourgon,Zora Modrusan,Howard M. Stern,Søren Warming,Frederic J. de Sauvage,Lukas C. Amler,Ru-Fang Yeh,David Dornan +19 more
TL;DR: MiR-221/222 may contribute to the aggressive clinical behavior of basal-like breast cancers because of their targeting of the 3′ untranslated region of TRPS1 (trichorhinophalangeal syndrome type 1), which is a member of the GATA family of transcriptional repressors.
153
HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.
Nancy Yu,Michael Kakunda,Victoria Pham,Jennie R. Lill,Pan Du,Matthew Wongchenko,Yibing Yan,Ron Firestein,XiaoDong Huang +8 more
TL;DR: HSP105 is overexpressed in many types of tumors, correlating with increased nuclear β-catenin protein levels and Wnt target gene upregulation and is a prognostic biomarker that correlates with poor overall survival in breast cancer patients as well as melanoma patients participating in the BRIM2 clinical study.
51
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Martin Weisser,Ru-Fang Yeh,Guillemette Duchateau-Nguyen,Giuseppe Palermo,Tri Quang Nguyen,Xiaoyan Shi,Susanna Stinson,Nancy Yu,Annika Dufour,Tadeusz Robak,Galina Salogub,Anna Dmoszynska,Philippe Solal-Celigny,Krzysztof Warzocha,Javier Loscertales,John Catalano,Loree Larratt,Viktor Rossiev,Isabelle Bence-Bruckler,Christian H. Geisler,Marco Montillo,Kirsten Fischer,Anna-Maria Fink,Michael Hallek,Johannes Bloehdorn,Raymonde Busch,Axel Benner,Hartmut Döhner,Nancy Valente,Michael Wenger,Stephan Stilgenbauer,David Dornan +31 more
TL;DR: Retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC, and may be a useful biomarker for patient selection in future trials.
15